[Asia Economy Reporter Hyungsoo Park] Canary Bio expects that the clinical trial of the combination therapy of oregovomab and PLD will meet the strategic demand to overcome resistance in existing anticancer drugs.
Ovarian cancer responds well to the first anticancer treatment but has a high recurrence rate. After multiple rounds of chemotherapy, the response rate to any drug can drop to 5-10%. The expanded clinical use of existing anticancer drugs such as platinum-based agents, Avastin, and PARP inhibitors can also induce acquired resistance.
Professor Jung Yoon Lee of Yonsei University Severance Hospital stated, "Since this is a combination therapy of PLD, which is not a platinum-based anticancer drug, and the new immuno-oncology drug oregovomab, we can expect therapeutic effects."
The research team at Yonsei University Severance Hospital recently introduced a second cohort applying the combination therapy of oregovomab with weekly paclitaxel, which was added after receiving approval from the Ministry of Food and Drug Safety. They added the combination therapy of oregovomab and weekly paclitaxel (cohort 2) to the combination of oregovomab and doxorubicin (PLD) (cohort 1). The patient scale was also increased from 28 to 58.
Canary Bio plans to expand the indication to recurrent ovarian cancer to provide treatment opportunities and increase its market share in the domestic and international ovarian cancer treatment markets.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
